)
Visual
test
Huadong Medicine Co
Huadong Medicine Co (000963) investor relations material
Huadong Medicine Co Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary3 Dec, 2025
Executive summary
Achieved operating revenue of RMB32.664 billion for Jan–Sep 2025, up 3.77% year-over-year; net profit attributable to shareholders reached RMB2.748 billion, up 7.24% year-over-year.
Q3 2025 revenue was RMB10.989 billion, up 4.53% year-over-year; net profit attributable to shareholders was RMB933 million, up 7.71% year-over-year.
Core pharmaceutical subsidiary Zhongmei Huadong saw revenue of RMB11.045 billion (Jan–Sep), up 11.10% year-over-year, and net profit of RMB2.475 billion, up 15.62%.
Innovative products contributed RMB1.675 billion in revenue, up 62% year-over-year.
Medical aesthetics segment revenue declined 17.90% year-over-year to RMB1.568 billion.
Financial highlights
Basic earnings per share for Jan–Sep 2025 was RMB1.5682, up 7.09% year-over-year.
Weighted average return on equity for Jan–Sep was 11.39%.
Total assets at period end were RMB39.93 billion, up 5.41% from year-end 2024.
Net cash flow from operating activities for Jan–Sep was RMB2.611 billion, up 4.17% year-over-year.
R&D expenses for Jan–Sep were RMB1.508 billion, up 58.92% year-over-year.
Outlook and guidance
Plans to continue executing annual operational plan in Q4 2025, focusing on research, production, and business activities to achieve full-year targets.
Preparing for national and commercial insurance negotiations for key innovative products in Q4 2025.
Medical aesthetics turnaround strategy?
R&D spend vs. financial expense management?
Innovative product commercialization outlook?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebPECO
2026 FFO per share growth guided at 5.5% with record occupancy and robust acquisitions. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
- 6 FebEMBASSY
Record revenue, NOI, and distributions highlight strong growth and robust segment performance. - 6 FebCRIRevenue fell and losses deepened, but ESA contracts and R&D projects drive future prospects.
- 6 FebNVDA
AI-driven digital twins and real-time simulation will transform engineering and manufacturing. - 6 FebTUPRS
Net income reached TRY 29.5 billion, with strong dividends and a robust net cash position. - 6 FebCPT
2025 results beat guidance; Sun Belt focus, asset sales, and share buybacks drive 2026 strategy. - 6 FebCRIH1 2025 saw a return to profit, record revenues, and strong cash from major space projects.
Next Huadong Medicine Co earnings date
Q4 202524 Apr, 2026
Huadong Medicine Co
Next Huadong Medicine Co earnings date
Q4 202524 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Huadong Medicine Co., Ltd. is engaged in the research, development, manufacturing, and distribution of pharmaceutical products. The company’s offerings include a wide range of prescription drugs, over-the-counter medications, and healthcare products used in fields such as oncology, nephrology, endocrinology, and immunology. In addition to pharmaceuticals, Huadong Medicine operates in the medical aesthetics and biotechnology sectors. The company is headquartered in Hangzhou, China, and its shares are listed on the SZSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage